rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LXRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
      Nov 11Yahoo FinanceLXRXJEF
      Lexicon Pharmaceuticals CEO Michael Exton buys $49,999 in shares
      Nov 9Investing.comLXRX
      What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceLXRX
      Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data and ...
      Nov 5Yahoo FinanceLXRX
      Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 5BenzingaLXRX
      Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
      Nov 5Yahoo FinanceLXRX
      Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
      Nov 5Yahoo FinanceLXRX
      Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

      THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call

      Oct 29Yahoo FinanceLXRX
      Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
      Oct 23Yahoo FinanceLXRX
      Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
      Oct 21Yahoo FinanceLXRX
      Cantor Fitzgerald Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)

      Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailLXRX
      Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Lexicon Pharmaceuticals (NASDAQ:LXRX

      Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time

      Oct 6BenzingaLXRX
      Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress

      The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...

      Oct 2Yahoo FinanceLXRX
      Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

      Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.

      Sep 30Seeking AlphaLXRX
      Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today | The Motley Fool

      An analyst at a prominent research firm initiated coverage of the

      Sep 28The Motley FoolLXRX
      Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

      Cantor starts Lexicon at overweight with an $8 price target. Read more here.

      Sep 28Seeking AlphaLXRX
      Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating

      Lexicon Pharmaceuticals (LXRX) shares rose 7.5% in Monday trading after Cantor Fitzgerald initiated

      Sep 28Yahoo FinanceLXRX
      Why is Lexicon Pharmaceuticals stock surging today?
      Sep 28Investing.comLXRX
      Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
      Sep 28Investing.comLXRX
      This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mo

      Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

      Sep 28BenzingaLXRX
      Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight
      Sep 28Investing.comLXRX
      Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target
      Sep 28Yahoo FinanceLXRX
      Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

      Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv

      Sep 20Yahoo FinanceLXRX
      Lexicon Pharmaceuticals at H.C. Wainwright conference: catalysts ahead
      Sep 14Investing.comLXRX
      Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens
      Sep 10Investing.comLXRX
      Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset
      Sep 9Investing.comLXRX
      Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

      THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY: Citi 2026 Biopharma Back to School Conference September 9, 2026, 11:20–11:55 AM (Eastern Time) 2026 Cantor Global Healthcare ConferenceSeptember 10, 2026, 3:20–3:50 PM (Eastern Time) H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14, 2026, 9:00–9:30 AM (Eas

      Sep 1Yahoo FinanceLXRX
      Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

      Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented yesterday at ESC Congres

      Aug 31Yahoo FinanceLXRX
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)

      Detailed price information for Maxcyte Inc (MXCT-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailLXRXMXCT
      Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

      LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll

      Aug 24Yahoo FinanceLXRXNVO
      Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851
      Aug 24Yahoo FinanceLXRX
      LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

      Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.

      Aug 24Yahoo FinanceLXRXNVO

      This is the newest page. Registered accounts read further back.